Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by Benedict16thon Jul 09, 2019 12:20pm
54 Views
Post# 29899517

RE:RE:Meir at it again ...

RE:RE:Meir at it again ...Out of context reply, when any public trated company does a PP there is and industry generally accepted understanding that the company has reasonable near term plans for M&A  and or pay debt. That is why investors bought the PP plus given his reputation at the time. As it turns out it appears that there were no realistic plans/strategies for M&A and as such the market sold the dud. The real questionn; Is any investor out there who would buy a new GUD PP now? I doubt it........
I would not either till such a time GUD redeams it's credentials with actions.  Burn me once and it's your fault burn me a second time and it is my fault. 
What ever euphoria and or trust was there in the past it is sadly all gone. In my oppinion Both Meir and GUD MNGT credentials are damged inestment goods as name calling eachother is not how to run a billion dollar public company regardless who is at fault. At this point  they both need to respectifully do the right thing and move out of the way for the benefit of rest of the investors.   Some time in life being in the wrong place at the wrong time you cannot win. 
Bullboard Posts